Answers are grounded in this paper and cite their sources.
Computational genomics study demonstrates high-accuracy immune subtyping in bladder cancer, suggesting improved risk stratification for personalized immunotherapy.
Bladder urothelial carcinoma (BLCA) exhibits marked heterogeneity, leading to variable treatment responses and prognoses across subtypes. Current molecular classification systems lack emphasis on immune-related genes, limiting their utility for guiding immunotherapy. Using TCGA transcriptome data, we identified 490 immune-related differentially expressed genes. The top 20% most representative genes were selected for subtype delineation via Non-negative Matrix Factorization (NMF), yielding 2 optimal subtypes. We then constructed an Exploration-Enhanced Grey Wolf Optimization-based Soft Voting (EGWO-SV) model, integrating Logistic Regression, XGBoost, and Random Forest as base learners. This model outperformed 9 classical machine learning methods (AUC 97.11%, Accuracy 90.00%, F1 88.24%). SHAP visualization highlighted CLEC2B and SULT1A1 as key genes for BLCA prognosis. Subtype analysis revealed significant survival disparities, with the high-risk group linked to advanced stages. EGWO-SV enables efficient BLCA subtyping, supporting precise diagnosis, personalized immunotherapy, and improved understanding of tumor heterogeneity.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: